Haematological Cancer Clinical Research Report Update
Explore the latest research findings and updates from the Haematological Cancer Clinical Advisory Group in their report dated 25/11/2020. Learn about the impact of COVID-19 on research efforts, insights from Professor Chris Whitty, and the progress towards restarting studies in the face of the pandemic.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Haematological Cancer Clinical Advisory Group Research Report 25/11/2020
The world faces an unprecedented challenge in our efforts to tackle the spread of COVID-19 and it is vital we harness our research capabilities to the fullest extent to limit the outbreak and protect life Professor Chris Whitty, Chief Medical Officer and NIHR Co-Lead
Pausing research, Urgent Public Health Research, Vaccines and more... NIHR Portfolio paused due to COVID-19 pandemic UPH Group set up on behalf of DHSC Restart Framework Viability Safety Site capacity 2nd wave guidance - protect research
NIHR CRN High Level Objectives Proportion of new commercial studies achieving RTT Recruitment to Time and Target Proportion of NHS Trusts, GP Practices and non-NHS sites recruiting in Portfolio studies Widening Participation Number of participants responding to the Participant Research Experience Survey Participant Experience Study setup time of 9 working days for UPH studies Urgent Public Health Percentage of paused commercial / non-commercial studies no longer paused at 31/03/2021 Restart
This data reflects the current national picture of restart for studies (cancer as managing specialty) The yellow group reflects the studies which have not been affected by COVID-19, e.g a study was suspended before the pandemic and remains suspended.
This data shows the restart progress for cancer studies by each participating LCRN
This data shows the national restart progress for cancer studies and haematological cancer studies Cancer overall Haematological cancer
This data reflects the Haematological cancer studies which the West of England is participating in by sites.
NIHR ODP Open data platform. Data on performance and restart across whole CRN, including all specialty areas NIHR Be Part of Research See which studies are open across the country National Cancer Research Institute Portfolio Maps View current national portfolio of open, closed and in set up cancer studies Find a Clinical Research Study (ODP) Search for a study to fit criteria. Good for horizon scanning, eligibility criteria
Research Delivery Manager claire.matthews@nihr.ac.uk Research Portfolio Facilitator rebecca.gleeson@nihr.ac.uk Cancer Sub-specialty Lead sallymoore5@nhs.net
